NCT04168957View on ClinicalTrials.gov

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

August 27, 2019

Study Completion Date

November 12, 2020

Conditions
Breastcancer
Interventions
DRUG

Oraxol

"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"

Trial Locations (5)

23561

Taipei Medical University Shuang Ho Hospital, New Taipei City

Unknown

China Medical University Hospital, Taichung

Taipei Medical University Hospital, Taipei

Tr-Service General Hospital, Taipei

Taipei Veterans Generla Hospital, Taipei, Taiwan, 11217

Sponsors

Lead Sponsor

Athenex, Inc.

Collaborators (1)

PharmaEssentia
All Listed Sponsors
collaborator

PharmaEssentia

INDUSTRY

lead

Athenex, Inc.

INDUSTRY

NCT04168957 - An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 | Biotech Hunter | Biotech Hunter